Franklin Biotechnology Discovery Fund

Portfolio Statistics

Assets

Total Fund AssetsAs of 12/31/2020 (updated monthly) $1,537.8 (M)
Net Assets - Class C As of 01/31/2021 (updated monthly) $68.9 (M)
P/E Ratio (12-mo Forward)As of 01/31/2021 (updated monthly) 17.27
P/B RatioAs of 01/31/2021 (updated monthly) 6.16

Positions As of 01/31/2021

Portfolio Details

Asset AllocationAs of 01/31/2021

[name] [value]
Equity 95.76%
Cash & Cash Equivalents 4.24%

Geographic BreakdownAs of 01/31/2021

[name] [value]
United States 84.27%
United Kingdom 4.77%
Cash & Cash Equivalents 4.24%
Denmark 2.17%
Canada 2.05%
Switzerland 1.40%
Netherlands 1.10%

sector breakdownAs of 01/31/2021

[name] [value]
Biotechnology 76.58%
Pharmaceuticals 13.12%
Life Sciences Tools & Services 4.55%
Cash & Cash Equivalents 4.24%
Diversified Capital Markets 1.26%
Other Diversified Financial Services 0.25%

TOP TEN HOLDINGSAs of 01/31/2021

43.83%
Other
0% 100%
[holdings-table-heading]
GILEAD SCIENCES INC 6.42%
VERTEX PHARMACEUTICALS INC 5.45%
REGENERON PHARMACEUTICALS INC 5.05%
AMGEN INC 4.98%
ILLUMINA INC 4.55%
GW PHARMACEUTICALS PLC 4.54%
IOVANCE BIOTHERAPEUTICS INC 3.96%
NOVAVAX INC 3.32%
PTC THERAPEUTICS INC 2.87%
BIOGEN INC 2.69%